For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more ...

Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs).

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

IP Group said on Monday that its portfolio company Istesso has reported results from a phase 2b study of its investigational ...

For rheumatoid arthritis patients with inadequate response to JAK inhibitors, new research suggests cycling to another JAKi ...

This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...

Researchers have developed a novel analytical method for tracking disease progression in patients that shows great potential ...

Like many autoimmune diseases, rheumatoid arthritis (RA) can be challenging to manage. However, research has shown promise ...